|
|
 |
|
SGMO: Sangamo Biosciences Inc - Stock News |
Enter Ticker:
|
|
| Nov 18, 2009 |
Sangamo Biosciences Down 17.2% Since SmarTrend's Sell Recommendation |
| Nov 18, 2009 |
Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS |
| Nov 10, 2009 |
Sangamo Biosciences Down 19.6% Since SmarTrend's Sell Recommendation |
| Nov 10, 2009 |
Conference Calls Today: 2-2:40 P.M. EDT |
| Nov 04, 2009 |
Sangamo BioSciences Reports Third Quarter 2009 Financial Results |
| Nov 04, 2009 |
Sangamo Biosciences Down 22% Since SmarTrend's Sell Recommendation |
| Nov 03, 2009 |
Sangamo BioSciences Announces Presentation at Merriman Curhan Ford's Investor Summit 2009 |
| Oct 28, 2009 |
Sangamo Biosciences Down 17.4% Since SmarTrend's Sell Recommendation |
| Oct 28, 2009 |
Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast |
| Oct 28, 2009 |
Sangamo BioSciences Research Collaborators Awarded Grant From California Institute for Regenerative Medicine to Develop Zinc Finger Nuclease-Based Stem Cell Therapy for HIV/AIDS |
| Oct 27, 2009 |
BUYINS.NET: BTI, BPFH, TYL, EEFT, OSTK, SGMO Expected To Be Higher After Earnings Releases on Wednesday |
| Oct 20, 2009 |
Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting |
| Oct 19, 2009 |
Sangamo Biosciences Down 5% Since SmarTrend's Sell Recommendation |
| Oct 16, 2009 |
BUYINS.NET: (SGMO) SqueezeTrigger Price is $7.356. There is $28,953,224.00 That Short Sellers Still Need To Cover |
| Oct 15, 2009 |
Sangamo Biosciences (SGMO) |
| |
| ZACKS COMMENTARY FOR SGMO |
| Nov 05, 2009 | Zacks Equity Research: Report for SGMO | | Oct 15, 2009 | Zacks Blog: Zacks Bull and Bear of the Day Highlights: Sangamo Biosciences, Inc., Conmed, Intel Corp., JPMorgan Chase & Company and CSX Corp. | | Oct 15, 2009 | Bull of the Day: Sangamo Biosciences (SGMO) | | Jun 30, 2009 | Zacks Blog: Sangamo’s Unique ZFP Advantage | | Feb 19, 2009 | Zacks Blog: Zacks Industry Rank Analysis Highlights: Myriad Genetics, Inc., Sangamo Biosciences, Inc., ZymoGenetics, Inc., Cytokinetics, Inc. and Xenoport Inc. | | Feb 18, 2009 | Zacks Industry Rank Analysis: Biotechs: A Trading Opportunity? |
|
|
Sponsored Links 
-0.15